Spheroid culture of LuCaP 147 as an authentic preclinical model of prostate cancer subtype with SPOP mutation and hypermutator phenotype

Cancer Letters

Volumn 351, Issue 2, 2014, Pages 272-280

  Saar, Matthias ^a,b   Zhao, Hongjuan ^a   Nolley, Rosalie ^a   Young, Sarah R ^a   Coleman, Ilsa ^c   Nelson, Peter S ^c   Vessella, Robert L ^d   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Drug testing; Preclinical model; Prostate cancer; Spheroids; SPOP

Indexed keywords

DOCETAXEL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MLN 0128; SUNITINIB; UNCLASSIFIED DRUG; ANILIDE; ANTIANDROGEN; BICALUTAMIDE; METRIBOLONE; NITRILE; NUCLEAR PROTEIN; REPRESSOR PROTEIN; SPOP PROTEIN, MOUSE; TOLUENESULFONIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE; GENE EXPRESSION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; IN VIVO STUDY; LUCAP 147 CELL LINE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; SPOP GENE; TUMOR SPHEROID; TUMOR XENOGRAFT; ANIMAL; GENETICS; METABOLISM; MULTICELLULAR SPHEROID; MUTATION; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

MUS;

ANDROGEN ANTAGONISTS; ANILIDES; ANIMALS; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; MALE; METRIBOLONE; MICE; MUTATION; NITRILES; NUCLEAR PROTEINS; PHENOTYPE; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; SPHEROIDS, CELLULAR; TOSYL COMPOUNDS;

EID: 84904755621     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.06.014     Document Type: Article

References (35)

1. Pienta K.J., Abate-Shen C., Agus D.B., Attar R.M., Chung L.W., Greenberg N.M., Hahn W.C., Isaacs J.T., Navone N.M., Peehl D.M., Simons J.W., Solit D.B., Soule H.R., VanDyke T.A., Weber M.J., Wu L., Vessella R.L. The current state of preclinical prostate cancer animal models. Prostate 2008, 68:629-639.
2. van Weerden W.M., Bangma C., de Wit R. Human xenograft models as useful tools to assess the potential of novel therapeutics in prostate cancer. Br. J. Cancer 2009, 100:13-18.
3. Kondo J., Endo H., Okuyama H., Ishikawa O., Iishi H., Tsujii M., Ohue M., Inoue M. Retaining cell-cell contact enables preparation and culture of spheroids composed of pure primary cancer cells from colorectal cancer. Proc. Natl. Acad. Sci. USA 2011, 108:6235-6240.
4. Young S.R., Saar M., Santos J., Nguyen H.M., Vessella R.L., Peehl D.M. Establishment and serial passage of cell cultures derived from LuCaP xenografts. Prostate 2013, 73:1251-1262.
5. Xu Y., Zhu X., Hahm H.S., Wei W., Hao E., Hayek A., Ding S. Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules. Proc. Natl. Acad. Sci. USA 2010, 107:8129-8134.
6. Claassen D.A., Desler M.M., Rizzino A. ROCK inhibition enhances the recovery and growth of cryopreserved human embryonic stem cells and human induced pluripotent stem cells. Mol. Reprod. Dev. 2009, 76:722-732.
7. Castro D.J., Maurer J., Hebbard L., Oshima R.G. ROCK1 inhibition promotes the self-renewal of a novel mouse mammary cancer stem cell. Stem Cells 2013, 31:12-22.
8. Liu X., Ory V., Chapman S., Yuan H., Albanese C., Kallakury B., Timofeeva O.A., Nealon C., Dakic A., Simic V., Haddad B.R., Rhim J.S., Dritschilo A., Riegel A., McBride A., Schlegel R. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am. J. Pathol. 2012, 180:599-607.
9. Kumar A., White T.A., MacKenzie A.P., Clegg N., Lee C., Dumpit R.F., Coleman I., Ng S.B., Salipante S.J., Rieder M.J., Nickerson D.A., Corey E., Lange P.H., Morrissey C., Vessella R.L., Nelson P.S., Shendure J. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc. Natl. Acad. Sci. USA 2011, 108:17087-17092.
10. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., Nickerson E., Chae S.S., Boysen G., Auclair D., Onofrio R.C., Park K., Kitabayashi N., MacDonald T.Y., Sheikh K., Vuong T., Guiducci C., Cibulskis K., Sivachenko A., Carter S.L., Saksena G., Voet D., Hussain W.M., Ramos A.H., Winckler W., Redman M.C., Ardlie K., Tewari A.K., Mosquera J.M., Rupp N., Wild P.J., Moch H., Morrissey C., Nelson P.S., Kantoff P.W., Gabriel S.B., Golub T.R., Meyerson M., Lander E.S., Getz G., Rubin M.A., Garraway L.A. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
11. Tomayko M.M., Reynolds C.P. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother. Pharmacol. 1989, 24:148-154.
12. Wettenhall J.M., Smyth G.K. LimmaGUI: a graphical user interface for linear modeling of microarray data. Bioinformatics 2004, 20:3705-3706.
13. Zhao H., Nolley R., Chen Z., Reese S.W., Peehl D.M. Inhibition of monoamine oxidase A promotes secretory differentiation in basal prostatic epithelial cells. Differ.; Res. Biol. Divers. 2008, 76:820-830.
14. Oh S.J., Erb H.H., Hobisch A., Santer F.R., Culig Z. Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways. Endocr. Relat. Cancer 2012, 19:305-319.
15. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
16. Karlsson H., Fryknas M., Larsson R., Nygren P. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp. Cell Res. 2012, 318:1577-1585.
17. Kunz-Schughart L.A., Freyer J.P., Hofstaedter F., Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 2004, 9:273-285.
18. Takagi A., Watanabe M., Ishii Y., Morita J., Hirokawa Y., Matsuzaki T., Shiraishi T. Three-dimensional cellular spheroid formation provides human prostate tumor cells with tissue-like features. Anticancer Res. 2007, 27:45-53.
19. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 1995, 332:1393-1398.
20. Saxena P., Trerotola M., Wang T., Li J., Sayeed A., Vanoudenhove J., Adams D.S., Fitzgerald T.J., Altieri D.C., Languino L.R. PSA regulates androgen receptor expression in prostate cancer cells. Prostate 2012, 72:769-776.
21. Geng C., He B., Xu L., Barbieri C.E., Eedunuri V.K., Chew S.A., Zimmermann M., Bond R., Shou J., Li C., Blattner M., Lonard D.M., Demichelis F., Coarfa C., Rubin M.A., Zhou P., O'Malley B.W., Mitsiades N. Prostate cancer-associated mutations in speckle-type POZ protein (SPOP) regulate steroid receptor coactivator 3 protein turnover. Proc. Natl. Acad. Sci. USA 2013, 110:6997-7002.
22. Zhang Y., Wang Y., Yuan J., Qin W., Liu F., Wang F., Zhang G., Yang X. Toll-like receptor 4 ligation confers chemoresistance to docetaxel on PC-3 human prostate cancer cells. Cell Biol. Toxicol. 2012, 28:269-277.
23. dit Faute M.A., Laurent L., Ploton D., Poupon M.F., Jardillier J.C., Bobichon H. Distinctive alterations of invasiveness, drug resistance and cell-cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant. Clin. Exp. Metastasis 2002, 19:161-168.
24. Fischbach C., Chen R., Matsumoto T., Schmelzle T., Brugge J.S., Polverini P.J., Mooney D.J. Engineering tumors with 3D scaffolds. Nat. Methods 2007, 4:855-860.
25. Karlsson H., Fryknas M., Larsson R., Nygren P. Loss of cancer drug activity in colon cancer HCT-116 cells during spheroid formation in a new 3-D spheroid cell culture system. Exp. Cell Res. 2012, 318:1577-1585.
26. Harma V., Virtanen J., Makela R., Happonen A., Mpindi J.P., Knuuttila M., Kohonen P., Lotjonen J., Kallioniemi O., Nees M. A comprehensive panel of three-dimensional models for studies of prostate cancer growth, invasion and drug responses. PLoS ONE 2010, 5:e10431.
27. Zhang L., Jiao M., Li L., Wu D., Wu K., Li X., Zhu G., Dang Q., Wang X., Hsieh J.T., He D. Tumorspheres derived from prostate cancer cells possess chemoresistant and cancer stem cell properties. J. Cancer Res. Clin. Oncol. 2012, 138:675-686.
28. Makhov P.B., Golovine K., Kutikov A., Teper E., Canter D.J., Simhan J., Uzzo R.G., Kolenko V.M. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol. Cancer Ther. 2012, 11:1510-1517.
29. Jeong C.W., Yoon C.Y., Jeong S.J., Hong S.K., Byun S.S., Kwak C., Lee S.E. The role of hypoxia-inducible factor-1alpha and -2alpha in androgen insensitive prostate cancer cells. Urol. Oncol. 2013, 31:1448-1456.
30. Schenone S., Brullo C., Musumeci F., Radi M., Botta M. ATP-competitive inhibitors of mTOR: an update. Curr. Med. Chem. 2011, 18:2995-3014.
31. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
32. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., Liu Q., Iorio F., Surdez D., Chen L., Milano R.J., Bignell G.R., Tam A.T., Davies H., Stevenson J.A., Barthorpe S., Lutz S.R., Kogera F., Lawrence K., McLaren-Douglas A., Mitropoulos X., Mironenko T., Thi H., Richardson L., Zhou W., Jewitt F., Zhang T., O'Brien P., Boisvert J.L., Price S., Hur W., Yang W., Deng X., Butler A., Choi H.G., Chang J.W., Baselga J., Stamenkovic I., Engelman J.A., Sharma S.V., Delattre O., Saez-Rodriguez J., Gray N.S., Settleman J., Futreal P.A., Haber D.A., Stratton M.R., Ramaswamy S., McDermott U., Benes C.H. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
33. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines - Part 1. J. Urol. 2005, 173:342-359.
34. Sobel R.E., Sadar M.D. Cell lines used in prostate cancer research: a compendium of old and new lines - Part 2. J. Urol. 2005, 173:360-372.
35. Scher H.I., Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J. Clin. Oncol.: Off. J. Am. Soc. Clin. Oncol. 2005, 23:8253-8261.